Breakthrough Kidney Drug Finerenone Shows Promise Beyond Diabetes

A significant breakthrough has been made in the treatment of kidney disease, as a trio of major studies has found that the drug finerenone may protect the kidneys and heart in far more people than previously thought. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has been shown to slow kidney disease progression and reduce the risks of kidney failure, heart failure, cardiovascular death, and overall mortality.

The findings, presented at the European Renal Association Congress in Glasgow, United Kingdom, and published in three leading medical journals - The Lancet, The New England Journal of Medicine, and JAMA - have significant implications for the treatment of chronic kidney disease (CKD). The benefits of finerenone were seen not only in patients with diabetes but also in those with non-diabetic CKD and certain forms of glomerular disease.

The FIND-CKD trial, led by Professor Hiddo Heerspink of The George Institute for Global Health and Professor Vlado Perkovic of UNSW Sydney, enrolled 1,584 people with non-diabetic CKD across 24 countries. Patients who received finerenone in addition to standard treatment experienced a significantly slower decline in kidney function compared with those receiving standard care alone. The study also found that finerenone reduced the combined risk of kidney failure, worsening CKD, heart failure, or cardiovascular death by 23%.

A second analysis, led by Associate Professor Brendon Neuen of The George Institute and published in JAMA, focused on participants with glomerular diseases. Among these patients, finerenone lowered the risk of kidney failure or CKD progression by 26% compared with placebo. The drug also reduced albuminuria, a measure of protein in the urine and an important sign of kidney damage, by 42% after 12 months.

In a third study published in The Lancet, researchers combined data from the FIND-CKD trial with two earlier phase III studies involving patients with diabetic CKD. The pooled analysis included 14,000 patients and found that finerenone significantly reduced the risk of kidney failure, heart failure, and cardiovascular death.

The implications of these findings are far-reaching, with the potential to improve the lives of millions of people worldwide. As the world grapples with the challenges of kidney disease, the discovery of finerenone's effectiveness in a broader range of patients offers new hope for those affected by this devastating condition.